In addition, incretin glucagon-like peptide 1 and the glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonist could alleviate the cognitive decline in AD mice by activating the insulin signaling pathways to maintain the glucose metabolism of astrocytes [135]. This evidence concerns the gene GCG and Alzheimer disease.